AlphaMeld Corporation
Shubham Mehra is an Analyst at InveniAI, a position held since August 2021. Prior experience includes serving as a Research Trainee at the Molecular Bacteriology lab from August 2018 to May 2021, where Shubham conducted molecular analyses on Helicobacter pylori, focusing on virulent genes and disease outcomes, as well as antibiogram profiling. Shubham has completed several internships, including a position at Mitra Industries Private Limited, studying bacterial pathogens in peritoneal dialysis patients, and at Manipal Hospitals, comparing gut microbiota across gastrointestinal diseases. Additional internships were completed at Panacea Biotec, working on clinical protocol development for a pneumococcal vaccine study, and at ICMR-NATIONAL Institute of Cholera and Enteric Diseases, analyzing gene expression in H. pylori from different patient groups. Shubham holds a dual degree in Biotechnology (B.Tech + M.Tech) from Amity University, Greater Noida Campus, completed in 2021, and received secondary and higher secondary education at J.D. Tytler School.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.